Anonymous ID: 932c70 March 5, 2019, 3:08 p.m. No.5526059   🗄️.is 🔗kun

>>5525726 (PB)

Cultists have used every trick in the book to keep cheap innovative treatments off the market and to maintain profitable toxic therapies in position.

 

One of the most egregious examples is insulin. Rapid acting insulins are one of the most widely used medications in the world. For years big pharma has known that rapid acting insulin causes amyloid tumors at repeat injection site. They have been so effective at suppressing this information that most endocrinologists have never even heard of them. They serious and very common.

 

One company Mannkind brought an alternative to market about ten years ago. FDA approval was delayed for years one time for a year Martin Shkreli

 

As a small biotech firm with no approved products on the market, MannKind was burning millions of dollars each month. The landscape was extremely competitive and, although 1,000+ biotech companies existed in North America, only the top 1% generated significant revenue (14). For most small biotech companies without approved products the major obstacle tended to be external funding, but this wasn’t the case for MannKind (15). CEO and founder Alfred Mann (hence the name “MannKind”) was a self-made billionaire who financed operations (16). Mann, a highly intelligent philanthropist, had already invented a glucose pump for diabetics. He aimed to do more for the diabetic community with the invention of Afrezza (15 & 16).

 

In 2010 MannKind completed clinical trials of Afrezza and filed for FDA approval (17). Management was confident the drug would be approved based on positive clinical trial data and ongoing interactions with the FDA (18). On Christmas day, ‘Pharma Grinch’ Martin Shkreli emailed the 12 FDA employees who were in charge of reviewing Afrezza’s application. Shkreli, who was completely transparent about his motives (e.g., he disclosed that he was short, or betting against, MannKind stock), urged them not to approve Afrezza (12 & 18). Despite the fact that his highest degree was a bachelor’s in business administration, Shkreli said he had performed an analysis of MannKind’s clinical data and concluded that their “clinical trial package was lacking” (9 & 10).

 

Management at MannKind was shocked when the FDA did not approve Afrezza due to flaws in the study design (18). This was highly unexpected because the FDA had previously approved the study design. Of note, the study design flaws were Shkreli’s main argument for why Afrezza should not be approved (12 & 15). The FDA’s decision meant MannKind had to run more clinical trials. For MannKind this meant spending millions more dollars, laying off 175+ employees, and obtaining major external financing in order to stay afloat (17 & 19).

 

https://jesscuest.com/article/martin-shkreli-hurt-mannkind/